1
/
of
1
Elabscience
SKU:PKSH033961
Recombinant Human Thymic Stromal Lymphopoietin/TSLP (R127A, R130A, C-10His)
Recombinant Human Thymic Stromal Lymphopoietin/TSLP (R127A, R130A, C-10His)
Regular price
$200.00 USD
Regular price
Sale price
$200.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant Human Thymic Stromal Lymphopoietin/TSLP (R127A, R130A, C-10HIS), a cutting-edge product designed to revolutionize the field of immunology. This meticulously engineered formulation combines the power of recombinant human thymic stromal lymphopoietin (TSLP) with the strategic mutations R127A, R130A, and C-10HIS, resulting in an unparalleled therapeutic solution.
Crafted with utmost precision, this recombinant human TSLP variant exhibits enhanced functionality and potency, offering a novel approach to modulating immune responses. The strategic mutations R127A and R130A have been strategically introduced to optimize the protein's receptor binding affinity, thereby augmenting its biological activity. Additionally, the incorporation of C-10HIS ensures facile purification and detection, facilitating streamlined research and development processes.
This product's exceptional quality is underscored by its rigorous manufacturing process, adhering to stringent industry standards. Employing advanced biotechnological techniques, the recombinant human TSLP (R127A, R130A, C-10HIS) is produced in a controlled laboratory environment, ensuring reproducibility and consistency in every batch.
The Recombinant Human Thymic Stromal Lymphopoietin/TSLP (R127A, R130A, C-10HIS) holds immense potential for various applications within the realms of immunotherapy, vaccine development, and immune system research. Its ability to modulate immune responses and promote immune cell maturation makes it an invaluable tool for elucidating intricate immunological mechanisms and designing targeted therapeutic interventions.
In conclusion, the Recombinant Human Thymic Stromal Lymphopoietin/TSLP (R127A, R130A, C-10HIS) represents a groundbreaking advancement in the field of immunology. With its enhanced functionality, optimized receptor binding affinity, and facile purification, this product is poised to revolutionize research and development efforts in immunotherapy and immune system modulation. Embrace the future of immunological innovation with this exceptional offering.
Crafted with utmost precision, this recombinant human TSLP variant exhibits enhanced functionality and potency, offering a novel approach to modulating immune responses. The strategic mutations R127A and R130A have been strategically introduced to optimize the protein's receptor binding affinity, thereby augmenting its biological activity. Additionally, the incorporation of C-10HIS ensures facile purification and detection, facilitating streamlined research and development processes.
This product's exceptional quality is underscored by its rigorous manufacturing process, adhering to stringent industry standards. Employing advanced biotechnological techniques, the recombinant human TSLP (R127A, R130A, C-10HIS) is produced in a controlled laboratory environment, ensuring reproducibility and consistency in every batch.
The Recombinant Human Thymic Stromal Lymphopoietin/TSLP (R127A, R130A, C-10HIS) holds immense potential for various applications within the realms of immunotherapy, vaccine development, and immune system research. Its ability to modulate immune responses and promote immune cell maturation makes it an invaluable tool for elucidating intricate immunological mechanisms and designing targeted therapeutic interventions.
In conclusion, the Recombinant Human Thymic Stromal Lymphopoietin/TSLP (R127A, R130A, C-10HIS) represents a groundbreaking advancement in the field of immunology. With its enhanced functionality, optimized receptor binding affinity, and facile purification, this product is poised to revolutionize research and development efforts in immunotherapy and immune system modulation. Embrace the future of immunological innovation with this exceptional offering.
Share
